About 1 200 reports

Respiratory Therapy News MARCH 2015

15 pages • By Espicom Business Intelligence

Industry Trend Analysis - Anti-PD1 Race Continues Despite BMS' NSCLC Approval WinIndustry Trend Analysis - Ruthigen Reverse Merger To Boost Pulmatrix' Respiratory Product DevelopmentIndustry Brief - AstraZeneca Completes Purchase Of Actavis' Branded Respiratory AssetsIndustry Brief - Sunovion Initiates SUN-101/eFlow Phase III Trial...

825 1 114 685
Mar 2015

Global Small Cell Lung Cancer Therapeutics Market 2015-2019

102 pages • By Infiniti Research Limited

About Small Cell Lung Cancer Cancer occurs when, after cell transformation, normal cells grow and multiply without control. Lung cancer is a common cause of mortality and morbidity in developed and developing countries. Smoking is considered to be the major cause of small cell lung cancer, though it also occurs in non-smokers. Lung cancer...

2 400 3 000 1 920
Mar 2015

Diagnostics and Therapeutics for Autism Spectrum Disorders: Global Markets

162 pages • By BCC Research

REPORT HIGHLIGHTSThe global autism spectrum disorders (ASD) market was valued at $346.2 million in 2013 and $360.9 million in 2014. This market is expected to grow to $412.7 million by 2019, a compound annual growth rate (CAGR) of 2.7%.This report provides:An overview of the regional and global markets...

5 320 6 650 4 256
Mar 2015

Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019

114 pages • By Infiniti Research Limited

About Acquired Orphan Blood Diseases TherapeuticsAcquired orphan blood diseases are rare disorders and are characterized by the body's inability to produce a sufficient amount of RBCs. This is basically because of the improper functioning of bone marrow to produce RBCs in the blood. This leads to a decrease in platelet counts, which can...

2 400 3 000 1 920
Mar 2015

A Competitive Analysis of the Global Breast Cancer Therapeutics Market : A New Class of Targeted Therapeutics Offers Novel Treatment Modalities to Treat Difficult Breast Cancers

68 pages • By Frost & Sullivan

Executive Summary•The global breast cancer therapeutics market is divided into x segments: hormonal therapy, targeted therapy, chemotherapy, and other therapy (for example, novel drugs in development).•About x hormonal therapies are available to treat breast cancer. The most common ones are aromatase inhibitors and selective...

4 000 5 000 3 200
Mar 2015

Big pharma Deals and Alliances of 2014

200 pages • By Currentpartnering

The Big Pharma Deals and Alliances of 2014 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2014. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the...

1 196 1 495 957
Mar 2015

Pharmaceutical Deals and Alliances of 2014

200 pages • By Currentpartnering

The Pharmaceutical Deals and Alliances of 2014 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2014. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities...

1 196 1 495 957
Mar 2015

Biotechnology Deals and Alliances of 2014

200 pages • By Currentpartnering

The Biotechnology Deals and Alliances of 2014 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2014. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of...

1 196 1 495 957
Mar 2015

Diagnostics Deals and Alliances of 2014

200 pages • By Currentpartnering

The Diagnostics Deals and Alliances of 2014 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2014. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of...

1 196 1 495 957
Mar 2015

Academic/Non-Profit Deals and Alliances of 2014

200 pages • By Currentpartnering

The Academic/Non-Profit Deals and Alliances of 2014 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2014. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities...

1 196 1 495 957
Mar 2015

Specialty Pharma Deals and Alliances of 2014

200 pages • By Currentpartnering

The Specialty Pharma Deals and Alliances of 2014 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2014. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities...

1 196 1 495 957
Mar 2015

Animal Health Deals and Alliances of 2014

200 pages • By Currentpartnering

The Animal Health Deals and Alliances of 2014 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2014. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of...

1 196 1 495 957
Mar 2015

Generic Pharma Deals and Alliances of 2014

200 pages • By Currentpartnering

The Generic Pharma Deals and Alliances of 2014 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2014. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities...

1 196 1 495 957
Mar 2015

Drug Delivery Deals and Alliances of 2014

200 pages • By Currentpartnering

The Drug Delivery Deals and Alliances of 2014 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2014. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of...

1 196 1 495 957
Mar 2015

Oncology Deals and Alliances of 2014

200 pages • By Currentpartnering

The Oncology Deals and Alliances of 2014 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2014. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the...

1 196 1 495 957
Mar 2015

Marketed Stage Deals and Alliances of 2014

200 pages • By Currentpartnering

The Marketed Stage Deals and Alliances of 2014 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2014. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities...

1 196 1 495 957
Mar 2015

Pre-Clinical Stage Deals and Alliances of 2014

200 pages • By Currentpartnering

The Pre-Clinical Stage Deals and Alliances of 2014 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2014. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities...

1 196 1 495 957
Mar 2015

Clinical Stage Deals and Alliances of 2014

200 pages • By Currentpartnering

The Clinical Stage Deals and Alliances of 2014 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2014. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities...

1 196 1 495 957
Mar 2015

Nonalcoholic Steatohepatitis: KOL Insight

By Firstword Pharma

Why This Report is Essential Expect a revolution in the treatment of nonalcoholic steatohepatitis (NASH) as a number of new therapies compete to become the first approved treatment for a disease that has high unmet clinical need. Nonalcoholic Steatohepatitis: KOL Insight reveals the critical views of US and European KOLs whose...

5 196 6 495 4 521
Mar 2015

CEL-SCI Corporation (CVM) - Financial and Strategic SWOT Analysis Review

50 pages • By Global Data

CEL-SCI Corporation (CVM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats....

100 125 80
Feb 2015

Respiratory Therapy News FEBRUARY 2015

13 pages • By Espicom Business Intelligence

Industry Trend Analysis - AstraZeneca Further Bolsters Respiratory PortfolioIndustry Trend Analysis - IPF ODD Status Advances PBI-4050 Toward SuccessIndustry Brief - GSK Launches Two Products In US For Asthma/COPDIndustry Brief - CHMP Adopts Positive Opinion On Abraxane For First-Line NSCLCIndustry Brief - Enrolment Begins...

825 1 114 685
Feb 2015

Chemotherapy Induced Anemia - Pipeline Review, H1 2015

54 pages • By Global Markets Direct

Chemotherapy Induced Anemia - Pipeline Review, H1 2015SummaryGlobal Markets Direct’s, ‘Chemotherapy Induced Anemia - Pipeline Review, H1 2015’, provides an overview of the Chemotherapy Induced Anemia’s therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Chemotherapy...

1 600 2 000 1 280
Feb 2015

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2015

74 pages • By Global Markets Direct

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2015SummaryGlobal Markets Direct’s, ‘Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2015’, provides an overview of the Chemotherapy Induced Peripheral Neuropathy’s therapeutic pipeline.This report provides comprehensive information...

1 600 2 000 1 280
Feb 2015

Northwest Biotherapeutics, Inc. (NWBO) - Financial and Strategic SWOT Analysis Review

41 pages • By Global Data

Northwest Biotherapeutics, Inc. (NWBO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities...

100 125 80
Feb 2015

Cesca Therapeutics Inc. (KOOL) - Medical Equipment - Deals and Alliances Profile

31 pages • By Global Data

SummaryCesca Therapeutics Inc. (Cesca) formerly ThermoGenesis Corp. is a medical equipment company. It carries out the research, development, and commercialization of cell based therapeutics for application in regenerative medicine. Its lead technology platform, SurgWerks is used for the collection, separation, storage and delivery...

200 250 160
Feb 2015

Respira Therapeutics, Inc. - Medical Equipment - Deals and Alliances Profile

16 pages • By Global Data

SummaryRespira Therapeutics, Inc. (Respira) is a pharmaceutical development company. The company offers dry powder inhaler technologies. Its product pipeline includes RT234 AOS PAH, RT234 AOS IPF, and RT234 AOS COPD. Respira also develops a portfolio of inhaled drug products for orphan pulmonary diseases. The company is capable...

200 250 160
Feb 2015

Tenax Therapeutics, Inc. (TENX) - Medical Equipment - Deals and Alliances Profile

30 pages • By Global Data

SummaryTenax Therapeutics, Inc. formerly Oxygen Biotherapeutics, Inc. develops medical and cosmetic products that efficiently deliver oxygen to tissues in the body. The company is currently developing Oxycyte, is a perfluorocarbon (PFC) therapeutic oxygen carrier and intended to improve oxygen delivery to damaged tissues. The...

200 250 160
Feb 2015

Renal Failure Global Clinical Trials Review, H1, 2015

121 pages • By Global Data

Renal Failure Global Clinical Trials Review, H1, 2015SummaryGlobalData's clinical trial report, “Renal Failure Global Clinical Trials Review, H1, 2015" provides data on the Renal Failure clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Renal Failure. It includes...

2 000 2 500 1 600
Feb 2015

Polycystic Kidney Disease Global Clinical Trials Review, H1, 2015

84 pages • By Global Data

Polycystic Kidney Disease Global Clinical Trials Review, H1, 2015SummaryGlobalData's clinical trial report, “Polycystic Kidney Disease Global Clinical Trials Review, H1, 2015" provides data on the Polycystic Kidney Disease clinical trial scenario. This report provides elemental information and data relating to the clinical...

2 000 2 500 1 600
Feb 2015

Proteinuria Global Clinical Trials Review, H1, 2015

82 pages • By Global Data

Proteinuria Global Clinical Trials Review, H1, 2015SummaryGlobalData's clinical trial report, “Proteinuria Global Clinical Trials Review, H1, 2015" provides data on the Proteinuria clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Proteinuria. It includes...

2 000 2 500 1 600
Feb 2015